scispace - formally typeset
H

Hana Jelínková

Researcher at Masaryk University

Publications -  8
Citations -  36

Hana Jelínková is an academic researcher from Masaryk University. The author has contributed to research in topics: Medicine & Minimal residual disease. The author has an hindex of 3, co-authored 5 publications receiving 14 citations.

Papers
More filters
Journal ArticleDOI

High‐throughput sequencing of T‐cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies

TL;DR: The proposed high‐throughput sequencing based method for the identification of clonal TRA gene rearrangements at the DNA level fills the existing gap in utilizing the TRA gene for a wide range of studies, including clonality assessment, MRD monitoring and clonal evolution analysis in different lymphoid malignancies.
Journal ArticleDOI

Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.

TL;DR: An analysis comparing the importance of flow cytometry (FCM) and real‐time quantitative polymerase chain reaction (PCR) in the assessment of MRD in adult ALL showed that both FCM and PCR MRD assessment methods are sensitive for survival prediction during induction.
Journal ArticleDOI

Very rare near‐haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR‐T therapy in 19‐year‐old male patient

TL;DR: Near‐haploid acute lymphoblastic leukemia is rare subgroup of the disease, which is very important due to very poor prognosis and resistance to treatment including novel monoclonal antibodies and CAR‐T therapy.
Journal ArticleDOI

Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype

TL;DR: In this article, the frequency and mutual associations of BCR-ABL1-like acute lymphoblastic leukemia (ALL) with a complex genomic background were studied, and the authors found that the frequency of mutations was positively associated with the survival of ALL patients.